Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
Phase 2 Completed
25 enrolled 11 charts
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
EARN
Phase NA Completed
33 enrolled
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Phase 1/2 Completed
307 enrolled 27 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
KEYVIBE-005
Phase 2 Completed
613 enrolled
CNSI-Fe(II)
Phase 1 Completed
19 enrolled 47 charts
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Phase 1 Completed
58 enrolled
PREFER
Completed
1,429 enrolled
ACTolog
Phase 1 Completed
38 enrolled
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Phase 1/2 Completed
79 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Phase 1 Completed
190 enrolled
Dragon
Phase NA Completed
52 enrolled
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Phase 1/2 Completed
48 enrolled
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Phase 1 Completed
29 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
Phase 1 Completed
47 enrolled
CAPABLE-IT
Phase NA Completed
56 enrolled
AcSé
Phase 2 Completed
334 enrolled
A Follow-up Study of Women Evaluated and Treated for Infertility
Completed
12,193 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Phase 1 Completed
71 enrolled
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Phase 1/2 Completed
49 enrolled
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
Phase 2 Completed
30 enrolled 20 charts
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Phase 1 Completed
15 enrolled
GASVERT
Phase 3 Completed
744 enrolled
DUET-2
Phase 1 Completed
150 enrolled
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Phase 1 Completed
17 enrolled 14 charts
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
WiZen
Completed
670,000 enrolled
DETECT
Completed
458 enrolled
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
Phase NA Completed
9 enrolled
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
FPA008-003
Phase 1 Completed
313 enrolled 30 charts
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Phase 1/2 Completed
444 enrolled 19 charts
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Phase 1 Completed
20 enrolled
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Phase 1/2 Completed
195 enrolled 51 charts
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Phase 2 Completed
5 enrolled 8 charts
Investigator Initiated Phase 1 Study of TBI-1201
Phase 1 Completed
18 enrolled
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled
PREMED-F1
Phase 3 Completed
27 enrolled